XBRU
TESB
Market cap1.45bUSD
Aug 03, Last price
21.55EUR
1D
0.94%
1Q
1.17%
Jan 2017
-38.07%
Name
Tessenderlo Group NV
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Tessenderlo Group N.V., a global entity established in 1919 and headquartered in Brussels, Belgium, is a subsidiary of Verbrugge NV. The company, which rebranded from Tessenderlo Chemie nv in June 2017, operates across four principal segments: Agro, Bio-Valorization, Industrial Solutions, and T-Power, serving diverse end markets such as agriculture, food, industry, construction, health, and consumer goods. The Agro division is dedicated to the manufacturing, marketing, and distribution of essential crop nutrients, including liquid and potassium sulfate fertilizers sold under brands like Thio-Sul, KTS, K-Row 23, CaTs, GranuPotasse, SoluPotasse, and K-Leaf. Additionally, it provides crop protection products such as LINEX and VELPAR herbicides, SEVIN insecticide, and SECTAGON fumigant. Through its Bio-Valorization segment, Tessenderlo Group transforms bio-residuals into a range of valuable products like gelatins, collagen peptides, proteins, and fats. These are supplied to various sectors, including food, pharmaceutical, health and nutrition, pet food, agriculture, aqua feed, animal feed, energy, biodiesel, oleo-chemistry, and sanitary markets. The Industrial Solutions arm manufactures and supplies plastic pipe systems and chemicals for water treatment. This segment also encompasses other industrial activities, including the production and sale of mining and industrial auxiliaries, alongside specialized services for treating and disposing of produced and flowback water from oil and gas exploration, and recovering industrial process fluids. Finally, the T-Power segment focuses on energy generation, utilizing a 425 MW combined cycle gas turbine to produce electricity.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||